➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Dow
McKesson
Baxter
Johnson and Johnson
Boehringer Ingelheim

Last Updated: September 22, 2020

DrugPatentWatch Database Preview

Patent: 9,486,531

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,486,531
Title:Dehydrated hydrogel inclusion complex of a bioactive agent with flowable drug delivery system
Abstract: The invention provides a controlled release biodegradable polymer formulation adapted for administering bioactive agents such as therapeutic proteins to a patient through implantation of a bolus that forms a depot within the patient\'s body tissues. The formulation includes a dehydrated inclusion complex of the bioactive agent within a hydrogel, wherein the hydrogel can comprise a polymerized polyalkyleneglycolyl diacrylate, and, optionally, polyalkyleneglycolyl monoacrylates, including methacrylates. Alternatively, the hydrogel can comprise hyaluronic acid, chitosan, agarose, polyvinylacetate, polyvinylpyrrolide, or polyvinylalcohol nanoparticles. The bioactive agent can be a macromolecular material, such as a protein. A method of forming the inventive formulation is also provided, as well as a method for using the formulation in the treatment of a malcondition in a patient in need thereof.
Inventor(s): Dadey; Eric (Furlong, PA), Watkins; Andrew (Drew) (Fort Collins, CO)
Assignee: INDIVIOR UK LIMITED (Slough, GB)
Application Number:12/995,956
Patent Claims:see list of patent claims

Details for Patent 9,486,531

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Lilly HUMULIN R insulin recombinant human INJECTABLE;INJECTION 018780 001 1982-12-02   Start Trial INDIVIOR UK LIMITED (Slough, GB) 2028-06-03 RX search
Lilly HUMULIN R KWIKPEN insulin human SOLUTION;SUBCUTANEOUS 018780 002 1982-12-02   Start Trial INDIVIOR UK LIMITED (Slough, GB) 2028-06-03 RX search
Lilly HUMULIN R insulin human SOLUTION;SUBCUTANEOUS 018780 004 1982-12-02   Start Trial INDIVIOR UK LIMITED (Slough, GB) 2028-06-03 RX search
Lilly HUMULIN R PEN insulin recombinant human INJECTABLE;INJECTION 018780 005 1982-12-02   Start Trial INDIVIOR UK LIMITED (Slough, GB) 2028-06-03 RX search
Imclone ERBITUX cetuximab VIAL; INTRAVENOUS 125084 001 2004-06-18   Start Trial INDIVIOR UK LIMITED (Slough, GB) 2028-06-03 RX Orphan search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 001 2004-02-26   Start Trial INDIVIOR UK LIMITED (Slough, GB) 2028-06-03 RX Orphan search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 002 2004-02-26   Start Trial INDIVIOR UK LIMITED (Slough, GB) 2028-06-03 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
McKinsey
Medtronic
Mallinckrodt
Merck
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.